Polymyalgia Rheumatica Market Anticipated To Witness Robust Growth, Surpassing 1.73 Billion By 2029

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Current Polymyalgia Rheumatica Market Size and Its Estimated Growth Rate?
There has been a substantial expansion in the polymyalgia rheumatica market size in the past few years. Its progression will see a rise from $1.28 billion in 2024 to $1.36 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 6.6%. Several factors account for this augmentation during the historical period, including increased alertness among TH*Care providers, escalated usage of corticosteroids, expansion in specialty clinics, the emergence of biologic treatments, and ascending TH*Care expenses.

In the coming years, the polymyalgia rheumatica market is anticipated to witness robust expansion. The prediction is for the market to climb to a value of $1.73 billion in 2029, corresponding to a compound annual growth rate (CAGR) of 6.2%. Multiple factors contribute to the predicted growth during this forecast period, including increased usage of biologics, the progression of precision medicine, quicker drug authorization processes, more comprehensive reimbursements, and broader clinical trials. Key trends anticipated during this forecast period encompass the creation of combination therapies, advancements in personalized medicine, the evolution of precision medicine, the increased incorporation of electronic health records, and progress in biomarkers.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

How Are Emerging Segments Shaping the Polymyalgia Rheumatica Market Landscape?
The polymyalgia rheumatica market covered in this report is segmented -

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Type: Adult, Geriatric, Periatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib
3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine
4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

Which Growth Factors Are Influencing Polymyalgia Rheumatica Market Expansion?
The increasing requirements for personalized medicinal treatments are predicted to accelerate the expansion of the polymyalgia rheumatica industry in the future. Personalized medicine, which is designed according to an individual's genetic code, lifestyle, and particular health challenges, leads to more successful results. The rising demand for such tailored treatments can be attributed to the developments in genetic studies, growing patient anticipation for customized treatments, and advancements in diagnostic technologies. Genetic explorations allow for a greater comprehension of individual genetic differences, permitting highly individualized treatment that targets specific genetic indicators. Personalized medicine can aid in picking the most beneficial drugs based on patient characteristics, leading to a safer yet more efficient therapy plan. For example, 16 new customized treatments for patients with rare diseases were approved by the Food and Drug Administration in 2023, a significant leap from six in 2022, as per the data of Personalised Medicine Coalition, a health-based organization in the US. Consequently, the surge in personalized medicine is stimulating the growth of the polymyalgia rheumatica industry. With the expansion of telemedical services, the polymyalgia rheumatica industry is also set for significant growth. Telemedical facilities employ digital technology like video conversations, phone calls, and internet messaging to deliver distant medicinal advice, diagnoses, therapies, and follow-up care, negating the need for physical encounters with patients. The expansion of telemedicine is a consequence of increasing need for comfortable and economical medical solutions. In particular, patients want convenience, especially for non-critical discussions, which telemedicine provides. The rise of telemedicine benefits polymyalgia rheumatica cases by implementing remote symptom tracking, medicine administration, and periodic follow-ups, all crucial for chronic pain and inflammation management. For instance, as per the figures from the Australian Bureau of Statistics, a government organization in Australia, 87.7% people used telehealth consultations in 2022-23 and this number rose to 89.2% in 2023-24. Thus, the surge in telemedical facilities is further driving the growth of the polymyalgia rheumatica industry.

Who Are the Dominant Players Across Different Polymyalgia Rheumatica Market Segments?
Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford TH*Care, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women's Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

What Are the Latest Developing Trends in the Polymyalgia Rheumatica Market?
Top industry players in the polymyalgia rheumatica market are concentrating on the creation of innovative drugs like interleukin-6 (IL-6) receptor blockers for more precise and successful treatment methods. Biological drugs, IL-6 receptor blockers halt the function of IL-6, a primary pro-inflammatory cytokine linked with autoimmune disorders. Through inhibiting IL-6, these drugs lessen inflammation and better the symptoms, thereby improving the life quality for patients suffering from PMR. In the month of February 2023, an announcement was made by the US-based biotech firm, Regeneron Pharmaceuticals, Inc., and the health company based in France, Sanofi, stating the Food and Drug Administration's (FDA) approval of Kevzara (sarilumab) for the treatment of adult polymyalgia rheumatica (PMR) patients who either are unresponsive to corticosteroids or unable to gradually stop their intake. Approved for PMR, the first and sole biologic, Kevzara functions through stoppage of IL-6-caused signaling. The drug's approval relied on a research study where 28.3% of patients using sarilumab reached consistent remission at the 52-week mark, compared to the 10.3% on placebo2. Kevzara, drawn into the body via subcutaneous injection once fortnightly, also has approval for treatment of active rheumatoid arthritis that ranges from moderate to severe levels. Currently, Sanofi's shares (SNY) are valued at $54.13 on the NASDAQ.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Geographic Regions Are Expected to Dominate the Polymyalgia Rheumatica Market in the Coming Years?
Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Polymyalgia Rheumatica Market?
2. What is the CAGR expected in the Polymyalgia Rheumatica Market?
3. What Are the Key Innovations Transforming the Polymyalgia Rheumatica Industry?
4. Which Region Is Leading the Polymyalgia Rheumatica Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.